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Abstract
Background
Little is known about the relative risk of common bacterial, viral, fungal, and parasitic infec-
tions in the general population of individuals exposed to systemic glucocorticoids, or about
the impact of glucocorticoid exposure duration and predisposing factors on this risk.
Methods and Findings
The hazard ratios of various common infections were assessed in 275,072 adults prescribed
glucocorticoids orally for15 d (women: 57.8%, median age: 63 [interquartile range 48–73]
y) in comparison to those not prescribed glucocorticoids. For each infection, incidence rate
ratios were calculated for five durations of exposure (ranging from 15–30 d to >12 mo), and
risk factors were assessed. Data were extracted from The Health Improvement Network
(THIN) primary care database. When compared to those with the same underlying disease
but not exposed to glucocorticoids, the adjusted hazard ratios for infections with significantly
higher risk in the glucocorticoid-exposed population ranged from 2.01 (95% CI 1.83–2.19; p
< 0.001) for cutaneous cellulitis to 5.84 (95%CI 5.61–6.08; p < 0.001) for lower respiratory
tract infection (LRTI). There was no difference in the risk of scabies, dermatophytosis and
varicella. The relative increase in risk was stable over the durations of exposure, except for
LRTI and local candidiasis, for which it was much higher during the first weeks of exposure.
The risks of infection increased with age and were higher in those with diabetes, in those
prescribed higher glucocorticoid doses, and in those with lower plasma albumin level. Most
associations were also dependent on the underlying disease. A sensitivity analysis con-
ducted on all individuals except those with asthma or chronic obstructive pulmonary disease
produced similar results. Another sensitivity analysis assessing the impact of potential
unmeasured confounders such as disease severity or concomitant prescription of chemo-
therapy suggested that it was unlikely that adjusting for these potential confounders would
have radically changed the findings. Limitations of our study include the use of electronic
medical records, which could have resulted in some degree of misclassification of the
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infectious outcomes; a possible reporting bias, as general practitioners could be more prone
to record an infection in those exposed to glucocorticoids; and a low number of events for
some outcomes such as scabies or varicella, which may have led to limited statistical power.
Conclusions
The relative risk of LRTI and local candidiasis is very high during the first weeks of glucocor-
ticoid exposure. Further studies are needed to assess whether low albumin level is a risk
factor for infection by itself (e.g., by being associated with a higher free glucocorticoid frac-
tion) or whether it reflects other underlying causes of general debilitation.
Introduction
More than 1% of the general population in the US and the UK receives systemic glucocorticoid
therapy, and this figure has increased by more than 30% over the last 20 y [1,2]. Many patients
are exposed to glucocorticoids for many weeks or months in primary care [1,2], especially for
respiratory (e.g., asthma), rheumatic (e.g., giant cell arteritis, rheumatoid arthritis), or neoplas-
tic conditions [1]. Even though the efficacy of glucocorticoids in the treatment of these condi-
tions is indisputable, they can be associated with severe adverse events. Infections are known
complications of systemic glucocorticoid exposure, even in those exposed for only a few days
or weeks [3]. A meta-analysis of randomized controlled trials (RCTs) published more than 25
y ago found that the overall risk of infections was 50% to 60% higher in the glucocorticoid-
exposed population compared to those receiving placebo [3]. The increase in risk is much
higher for opportunistic infections (e.g., tuberculosis, listeriosis, invasive fungal infections) and
in specific populations (e.g., allogeneic bone marrow transplant, solid organ transplant) [4–10].
Surprisingly, very few studies have focused on the risk of various common infectious condi-
tions in the general population of glucocorticoid-treated patients, and it is unclear whether
there is a differential risk regarding bacterial, viral, fungal, and parasitic infections. Moreover,
because previous studies were conducted in selected populations and used different methods,
the impact of the underlying condition on the risk of infection is difficult to assess. Further,
limited evidence is available regarding predisposing factors that may contribute to an increased
risk of infection in individuals.
In this study, we aimed to (1) assess the relative risks of various common bacterial, viral,
parasitic, and fungal infections in people prescribed systemic glucocorticoids in primary care,
(2) compare these relative risks between different durations of glucocorticoid exposure, and (3)
identify clinical and biological factors associated with the risk of infectious events in individuals
prescribed systemic glucocorticoids.
Methods
All methods were prespecified unless otherwise noted.
Ethics
The Health Improvement Network (THIN) scheme for obtaining patient data and providing
them in anonymized form to researchers was approved by the National Health Service South-
East Multicentre Research Ethics Committee in 2002. The present study was approved by the
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pulmonary disease; IQR, interquartile range; LRTI,
lower respiratory tract infection; OR, odds ratio; RCT,
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The Health Improvement Network.
University College London THIN steering committee and by the THIN scientific review com-
mittee (number 14–072).
Data Source: The Health Improvement Network
Approximately 98% of the population in the UK is registered with a general practitioner.
THIN is a database of anonymized electronic medical records from UK general practices. Par-
ticipating general practitioners systematically and prospectively retrieve and enter clinical
information on patients, including demographics data, diagnoses, and prescriptions, so that
the database provides a longitudinal medical record for each patient. THIN is representative of
the UK population, and comparisons to external statistics and other independent studies have
shown that both the clinical diagnostic and prescribing information is well recorded and accu-
rate [11,12]. The data are entered in routine general practice and therefore reflect “real life”
clinical care. Prescribing is well recorded in terms of general practitioner prescriptions since
the computerized entry made by the doctor is also used to issue a prescription to the patient.
To date, THIN includes data from almost 600 general practices and more than 12 million indi-
viduals. For this study, we used data from 1 January 2000 to 31 December 2012 from all general
practices that contributed to the database during this period. The data used for this study were
obtained from a license to THIN. For further information on access to the database, please con-
tact IMS Health (contact details can be found at http://www.csdmruk.imshealth.com/index.
html).
Identification of Glucocorticoid Prescriptions
In THIN, each prescription of a drug is recorded as a code referenced to the relevant chapter in
the British National Formulary [13]. We selected all synthetic glucocorticoids prescribed orally,
and this included prednisolone, prednisone, dexamethasone, triamcinolone, betamethasone,
methylprednisolone and deflazacort. In the case of multiple consecutive prescriptions, we con-
sidered that the prescriptions were part of a single course of therapy if the previous prescription
was issued less than 1 mo earlier, in order to take into account the persistence of glucocorticoid
action on immunity during the days following stopping glucocorticoid use. The start of a
course was defined as the day of the first prescription. The end of a course was defined as the
last day of the last prescription. These dates were derived from two variables available in the
database: total number of pills prescribed and number of pills to be taken per day. The baseline
daily dosage was calculated from the first glucocorticoid prescription. It was derived from the
number of pills prescribed per day multiplied by the dosage of each pill calculated in predni-
sone equivalent.
Identification of Infectious Events
All diagnoses and symptoms are recorded in THIN using the Read classification system [14].
This classification was used to create medical lists that enabled us to identify cases of three bac-
terial (i.e., septicemia, lower respiratory tract infection [LRTI], cutaneous cellulitis), two viral
(i.e., herpes zoster, varicella), one parasitic (i.e., scabies), and two fungal (i.e., local candidiasis,
dermatophytosis) infections recorded in the database (code lists available in S1 Table). These
infections were chosen because they cover a set of bacterial/viral/fungal/parasitic and local/sys-
temic infections frequently diagnosed in primary care. We initially planned to include infec-
tious colitis based on previous work suggesting an association between infectious colitis and
glucocorticoid exposure, but exploratory work indicated that this infection was poorly recorded
in primary care. In order to ensure that we identified true index cases, we chose to be specific
rather than sensitive in choosing the codes relevant to infections. We restricted our choice to
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those infections for which there was a precise code. Hence, for septicemia, we restricted the
codes to bacterial septicemia. For instance, those relating to “herpes simplex septicemia” or
“candidal septicemia” were excluded. Likewise, the codes selected for bacterial LRTI were spe-
cific to bacterial agents, and codes such as “viral pneumonia” or “rheumatic pneumonia” or
value codes such as “chest infection” or “bronchitis” were excluded. Finally, the codes selected
for cutaneous cellulitis were again specific to the diagnosis, and imprecise codes such as “bacte-
rial skin infections” or “fasciitis unspecified” were excluded (see S1 Table). In cases of several
records of the same type (e.g., recurrent herpes zoster or several records for an episode of
chronic local candidiasis or dermatophytosis) during the glucocorticoid exposure period (for
exposed individuals) or the at-risk period (for unexposed individuals; see below), the date of
the first record was used. Lastly, all patients with an infection recorded within the first 15 d of
glucocorticoid initiation were excluded from the analyses, as the symptoms associated with the
diagnosed infection may have been the reason for prescribing the glucocorticoid rather than
the infection being the consequence of glucocorticoid exposure (i.e., protopathic bias). We did
the same for the unexposed populations and thus excluded from the analyses all patients with
an infectious event recorded within 15 d after the randomly selected “index date.”
Glucocorticoid-Exposed Group
We identified all adults who were prescribed at least one course of oral glucocorticoid for at
least 15 d. As it is likely that those who have had a severe infection in the past while being
treated with glucocorticoids are less likely to be re-prescribed glucocorticoids, we chose to
include only people at their first glucocorticoid exposure. As events recorded within the first 6
mo of registration are more likely to represent retrospective recording of a past history rather
than a new episode of a problem, we selected only people who started glucocorticoids at least 6
mo after their registration in order to ensure capturing people with incident rather than preva-
lent prescriptions. The medical diagnosis recorded on the date of starting glucocorticoids was
used as the indication for the glucocorticoid prescription. If there was no medical diagnosis
recorded on this date, we searched for seven relevant conditions (i.e., asthma, chronic obstruc-
tive pulmonary disease [COPD], rheumatoid arthritis, inflammatory bowel disease, polymyal-
gia rheumatica/giant cell arteritis, connective tissue disease [lupus erythematosus,
dermatomyositis, polymyositis, systemic sclerosis or undifferentiated connective tissue dis-
ease], and cancer) entered in the records up to 1 y prior to or after this prescription. For those
with two (or more) of these conditions (e.g., COPD and cancer) recorded in the medical file,
we took into account the condition recorded closest to when the glucocorticoid prescription
was issued.
Unexposed Groups
Two comparison groups were identified. The first was a random sample of people who were
not prescribed glucocorticoids (unexposed population #1), and the second was a random sam-
ple of people not prescribed glucocorticoids but with a diagnosis of the same underlying disease
of interest as the exposed patients (unexposed population #2). People exposed to glucocorti-
coids for any duration of exposure at any time after registration in THIN were excluded from
the control populations. We selected up to three unexposed individuals from each unexposed
group (without and with the same underlying disease of interest) for every exposed individual.
When selecting the unexposed groups, we stratified the samples in terms of sex and age (within
10-y age bands) to ensure the distribution of these groups was similar to that of the glucocorti-
coid-exposed group. For each unexposed individual, a randomly selected “index date” was
defined at least 6 mo after their registration. This “index date” was defined as the start of the at-
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risk period. The end of the at-risk period was also randomly defined, at least 15 d after the
“index date,” so that the at-risk period of the unexposed individuals was similar to the exposure
period of the exposed individuals.
Biological Data
We searched the medical file of all glucocorticoid-exposed patients included in the study in
order to extract data regarding lymphocyte count and albumin level measured before record of
the infectious event (or before a randomly defined date during exposure for those who did not
have any of the infections of interest recorded). After exploratory work, we chose to include in
the analyses biological data recorded within the period ranging from 3 mo to 1 d before these
dates. In cases of several available lymphocyte counts and albumin levels during the period of
interest, means were calculated and used in the analyses.
Statistical Analysis
For each participant, follow-up time (i.e., exposure or at-risk period) was accrued from 15 d
after the glucocorticoid start date (in the exposed population) or the index date (in the unex-
posed population) until the date of the infectious outcome, the end of the at-risk period, the
date of leaving the practice, the date of death, or the end of the study period, whichever
occurred first. First, we compared the exposed to the unexposed groups to assess the hazard
ratios of infections associated with the prescription of glucocorticoids using Cox proportional
hazards models adjusted for age, sex, use of another immunosuppressant (i.e., methotrexate,
azathioprine, cyclosporine, or mycophenolate mofetil; coded as a binary variable: “0” if no use
of another immunosuppressant during the exposure/at-risk period and “1” if at least one pre-
scription of any immunosuppressant during this time period), past medical history of diabetes,
and, for the comparison with the second unexposed group, the underlying disease. Second, for
each first episode of infection, standardized incidence rate ratios were calculated during five
durations of exposure (i.e., 15–30 d, 1–3 mo, 4–6 mo, 7–12 mo,>12 mo) in order to assess
whether there was differential risk according to the duration of exposure. Lastly, risk factors for
infections in those exposed to systemic glucocorticoids were assessed using Cox proportional
hazards models comparing those with an infectious outcome during glucocorticoid exposure
to those without.
We further conducted three types of sensitivity analyses. In the first sensitivity analysis, we
excluded from the analyses all patients with asthma or COPD in order to ensure that the rela-
tive risk variations over duration of exposure were not related to the high proportion of people
with these two conditions in the study population. In the second sensitivity analysis, we
assessed risk factors for infection in those exposed to glucocorticoids after excluding all infec-
tions recorded within 1 mo after glucocorticoid initiation rather than 15 d. In the third sensitiv-
ity analysis, because we found that the underlying condition could be strongly associated with
the risk of some infectious outcomes (e.g., asthma/COPD with LRTI, cancer with septicemia),
we tried to estimate the impact of some unmeasured confounders, such as severity of the dis-
ease being treated or other concomitant prescriptions such as chemotherapy, on these findings
by using a Schneeweiss rule-out approach [15]. The proportional hazards assumption for Cox
models was checked graphically using the Schoenfeld residuals. No interaction term was
included in the models. Continuous variables are presented as median (interquartile range
[IQR]). Categorical variables are presented as proportions. The groups’ characteristics were
compared using the Chi2 test for comparisons of proportions and the Wilcoxon rank-sum test
for comparisons of medians. All statistical tests were two-sided. A p-value of<0.05 was consid-
ered statistically significant. All analyses were done using Stata, version 11.2, except for the
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Schneeweiss rule-out approach, which was performed in Excel as described by Sebastian
Schneeweiss [15,16].
Results
Study Populations
In total, 275,072 adults were prescribed at least one course of oral glucocorticoids for15 d
during the study period (women: 57.8%, median age: 63 [IQR 48–73] y). For 167,626 (60.9%)
of them (women: 57.8%, median age: 65 [IQR 50–75] y), glucocorticoids were prescribed for
one of the seven diseases of interest, i.e., asthma, COPD, rheumatoid arthritis, inflammatory
bowel disease, polymyalgia rheumatica/giant cell arteritis, cancer, or connective tissue disease
(Fig 1). The characteristics of both the exposed and the unexposed populations are reported in
Table 1. Those prescribed glucocorticoids were more likely to have a past history of diabetes
and were much more frequently exposed to other immunosuppressants than those not pre-
scribed glucocorticoids (Table 1).
Risk of Infection
The numbers of infectious outcomes of interest are reported in Table 2. The most frequently
recorded infectious event both in the exposed and unexposed populations was LRTI (4.3% of
all glucocorticoid-exposed patients compared to 0.7% in the unexposed patients), while the
least frequently recorded were varicella and scabies (less than 0.1% in both exposed and unex-
posed individuals). The adjusted hazard ratios are reported in Fig 2. The risk of each infection
was increased in the overall population of glucocorticoid-exposed individuals compared to
those not exposed to glucocorticoids (Fig 2), with adjusted hazard ratios ranging from 1.22
(95% CI 1.08–1.37; p = 0.001) for dermatophytosis to 5.42 (95% CI 5.23–5.61; p< 0.001) for
LRTI. When people prescribed systemic glucocorticoids for one of the seven diseases of interest
were compared to those with the same underlying disease but unexposed to glucocorticoids
(Fig 3), we still observed large effects for LRTI and local candidiasis (adjusted hazard ratio 5.84
[95% CI 5.61–6.08] and 5.75 [95% CI 5.28–6.26], respectively; p< 0.001). For other infections,
the increased risk was lower, around 2-fold, and there was no difference in the risk of scabies
(p = 0.25), dermatophytosis (p = 0.97), and varicella (p = 0.20).
Relative Increase of Risk with Duration of Exposure
When those exposed to glucocorticoids were compared to those with the same underlying con-
ditions but not exposed to glucocorticoids, we found that relative risk of a first episode of each
infection varied according to the type of infection (Fig 4). The relative increase in risk was
quite stable over duration of exposure for herpes zoster, septicemia, and cutaneous cellulitis.
For LRTI and local candidiasis, risk was highest during the first weeks of exposure and
markedly decreased thereafter.
Clinical Risk Factors for Infection in Those Exposed to Glucocorticoids
In order to assess factors associated with the risk of infection in the glucocorticoid-exposed
population, those with an infectious outcome during glucocorticoid exposure were compared
to those for whom no infectious outcome was recorded during glucocorticoid exposure. We
found that the risk of infection increased with age and was higher in those with diabetes and in
those prescribed a higher dosage of glucocorticoids (Table 3). The underlying condition was
also strongly associated with the infectious outcome. For instance, people with asthma or
COPD were at higher risk of LRTI, and those with cancer were at higher risk of septicemia or
Glucocorticoids and Infections
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local candidiasis. Overall, patients with polymyalgia rheumatica/giant cell arteritis were at
lower relative risk of infection than those with another underlying disease. Interestingly, the
risk of infectious event was not increased by a concomitant prescription of another immuno-
suppressant, except for herpes zoster.
Biological Risk Factors for Infection in Those Exposed to
Glucocorticoids
Both lymphocyte count and albumin level were available before the infectious event (or a ran-
domly selected date for those with no infectious outcome) in 34,401 (12.5%) out of the 275,072
glucocorticoid-exposed individuals. These patients were older, more frequently had polymyal-
gia rheumatica/giant cell arteritis or cancer, and received a higher dosage of glucocorticoids
than those with no lymphocyte count and albumin level available (S2 Table). When analyzing
the data obtained in this population, we found that the risk of all infections but herpes zoster
decreased as the albumin level increased. On the other hand, the risk of infection was not asso-
ciated with lymphocyte count, except for a moderate decrease in risk of cutaneous cellulitis in
those with higher lymphocyte count (Table 4).
Fig 1. Study flowchart.
doi:10.1371/journal.pmed.1002024.g001
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Sensitivity Analyses
In order to ensure that the relative risk variations over duration of exposure observed for LRTI
and local candidiasis (Fig 4) were not related to the high prevalence of people with asthma and
COPD in our study population (as they could be at higher risk of LRTI and thrush on account
of their underlying disease and their use of inhaled glucocorticoids), we ran a separate analysis
Table 1. Study populations.
Characteristic All GC-Exposed
Patients
(n = 275,072)
Unexposed
Population #1
(Stratiﬁed on Age
and Sex)
(n = 626,339)
p-
Value
Patients Exposed to
GC for One of the
Seven Diseases of
Interest (n = 167,626)
Unexposed Population
#2 (Stratiﬁed on Age,
Sex, and Underlying
Disease) (n = 334,966)
p-
Value
Age, years* 63 (48–73) 62 (46–74) 65 (50–75) 61 (46–74)
Women* 158,999 (57.8%) 363,290 (58.0%) 96,892 (57.8%) 187,709 (56.0%)
Start/index date Apr 2007 (Jan
2004–Apr 2010)
Jun 2007 (Mar 2004–
Sep 2010)
<0.001 Apr 2007 (Feb 2004–
May 2010)
May 2007 (Aug 2003–Sep
2010)
<0.001
Underlying disease <0.001
Asthma — — 62,163 (37.1%) 155,224 (46.4%)
COPD — — 34,995 (20.9%) 56,642 (16.9%)
Cancer — — 26,502 (15.8%) 78,745 (23.5%)
Polymyalgia rheumatica/giant
cell arteritis
— — 23,254 (13.9%) 5,804 (1.7%)
Inﬂammatory bowel disease — — 9,614 (5.7%) 15,867 (4.7%)
Rheumatoid arthritis — — 7,006 (4.2%) 14,169 (4.2%)
Connective tissue disease — — 4,092 (2.4%) 8,515 (2.6%)
Past history of diabetes 40,551 (14.7%) 67,136 (10.7%) <0.001 24,986 (14.9%) 41,956 (12.5%) <0.001
Duration of GC exposure,
days
Median, days 33 (21–70) — 36 (22–77) —
15–30 d 129,292 (47.0%) — 74,296 (44.3%) —
1–3 mo 90,945 (33.1%) — 56,863 (33.9%) —
4–6 mo 26,728 (9.7%) — 17,187 (10.3%) —
7–12 mo 16,460 (6.0%) — 11,309 (6.7%) —
>12 mo 11,647 (4.2%) — 7,971 (4.8%) —
Initial GC daily dosage**
Median, mg 15 (10–30) — 20 (10–30) —
<20 mg 140,031 (50.9%) — 81,481 (48.6%) —
20–50 mg 123,478 (44.9%) — 78,677 (46.9%) —
>50 mg 11,5363 (4.2%) — 7,468 (4.5%) —
Other
immunosuppressants***
<0.001 <0.001
Methotrexate 4,406 (1.6%) 748 (0.1%) 3,104 (1.9%) 3,031 (0.9%)
Azathioprine 3,993 (1.5%) 101 (<0.1%) 2,203 (1.3%) 537 (0.2%)
Cyclosporine 760 (0.3%) 57 (<0.1%) 161 (0.1%) 50 (<0.1%)
Mycophenolate mofetil 907 (0.3%) 24 (<0.1%) 239 (0.1%) 21 (<0.1%)
Data are given as median (IQR) or n (percent).
*Unexposed populations stratiﬁed on these variables.
**Prednisone equivalent.
***During exposure/at-risk period.
GC, glucocorticoid.
doi:10.1371/journal.pmed.1002024.t001
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on all patients excluding those with asthma or COPD (S1 Fig). We found that the relative risks
over duration of exposure were similar to those of the overall population.
We also assessed risk factors of infection in those exposed to glucocorticoids after excluding
all infections recorded within 1 mo after glucocorticoid initiation, rather than 15 d. Once
again, the results were similar (S3 Table).
Lastly, we sought to assess the impact of potential confounders on the risk of some infec-
tious outcomes. For instance, we hypothesized that the high observed risk of LRTI in patients
with asthma or COPD could be associated with the severity of the underlying disease (the
severity being associated with both the risk of LRTI and the risk of glucocorticoid prescription,
and therefore being an unmeasured confounder). Assuming that 40% to 60% of those with
asthma/COPD had a more severe condition that increased the risk of LRTI independently of
glucocorticoid exposure (corresponding to a confounder prevalence in the overall study
Table 2. Infectious events recorded during the exposure/at-risk period.
Variable All GC-Exposed
Patients
(n = 275,072)
Unexposed Population #1
(Stratiﬁed on Age and Sex)
(n = 626,339)
Patients Exposed to GC for
One of the Seven Diseases of
Interest (n = 167,626)
Unexposed Population #2
(Stratiﬁed on Age, Sex, and
Underlying Disease)
(n = 334,966)
Total exposure/at-risk
time, person-years
64,240 136,870 41,687 80,210
Infection, n (percent)
Septicemia 283 (0.1%) 133 (<0.05%) 185 (0.1%) 173 (0.5%)
LRTI 11,756 (4.3%) 4,662 (0.7%) 8,625 (7.6%) 4,432 (1.3%)
Cutaneous cellulitis 2,149 (0.8%) 1,604 (0.3%) 1,392 (0.8%) 1,235 (0.4%)
Herpes zoster 837 (0.3%) 640 (0.1%) 555 (0.3%) 453 (0.1%)
Varicella 24 (<0.05%) 23 (<0.05%) 13 (<0.05%) 26 (<0.05%)
Local candidiasis 2,592 (0.9%) 1,304 (0.2%) 1,857 (1.1%) 998 (0.3%)
Dermatophytosis 510 (0.2%) 882 (0.1%) 322 (0.2%) 584 (0.2%)
Scabies 147 (0.1%) 177 (<0.05%) 58 (<0.05%) 95 (<0.05%)
GC, glucocorticoid.
doi:10.1371/journal.pmed.1002024.t002
Fig 2. Risk of infection in the glucocorticoid-exposed group compared to those unexposed to
glucocorticoids. *Models adjusted for sex, age, diabetes, and use of other immunosuppressants. **p-
Value < 0.001 for all infections except for dermatophytosis, p = 0.001.
doi:10.1371/journal.pmed.1002024.g002
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population of approximately 20% to 30%), the Schneeweiss rule-out approach analysis sug-
gested that the severity of asthma/COPD would have to be very strongly associated with both
glucocorticoid exposure and LRTI to fully explain the observed result (S2 Fig).
Because we found that the risk of septicemia was very strongly associated with the underly-
ing disease cancer, we also assessed the impact of concomitant chemotherapy prescription in
those with cancer (which can be associated with the risk of both septicemia and glucocorticoid
prescription) on the risk of septicemia. As it was difficult to find estimates of the proportion of
cancer patients prescribed chemotherapy, we carried out analyses assuming that 25%, 50%,
and 75% of the individuals with cancer had chemotherapy (corresponding to a confounder
prevalence in the overall study population of approximately 5%, 10%, and 15%, respectively).
The analysis suggested that chemotherapy would have to be strongly associated with glucocor-
ticoid exposure and septicemia to fully explain the observed results (S3 Fig).
Fig 3. Risk of infection in glucocorticoid-exposed patients with one of the seven diseases of interest
compared to those with the same underlying diseases but unexposed to glucocorticoids. *Models
adjusted for sex, age, diabetes, use of other immunosuppressants, and the underlying disease. **p-
Value < 0.001 for all infections except for scabies, p = 0.25; varicella, p = 0.20; and dermatophytosis,
p = 0.97.
doi:10.1371/journal.pmed.1002024.g003
Fig 4. Incidence rate ratios according to duration of glucocorticoid exposure.
doi:10.1371/journal.pmed.1002024.g004
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Discussion
In this population-based cohort study, we found that the risk of some bacterial, viral, and fun-
gal infections was 2- to 6-fold higher in people prescribed oral glucocorticoids than in people
matched for age, gender, and the underlying disease. We did not demonstrate an increase in
risk for varicella, dermatophytosis, or scabies in the glucocorticoid-treated population, after
adjustment for the underlying condition. The relative risk of infection depended largely on the
type of infection. The relative increase in risk for LRTI and local candidiasis was highest during
the first weeks of exposure and markedly decreased thereafter. The risk of infection increased
with age and was higher in those with diabetes, in those prescribed a higher dosage of glucocor-
ticoid, and in those with lower plasma albumin level. It also markedly depended on the under-
lying disease.
Many studies have reported on the impact of systemic glucocorticoid exposure on the
occurrence of specific mycobacterial, fungal, or parasitic opportunistic infections in specific
glucocorticoid-treated populations [4–6,9,10]. Other studies have focused on the risk of more
common infections (mostly bacterial infections) in specific populations. In the study by
Table 3. Risk factors for infection in the overall population exposed to systemic glucocorticoids (n = 275,072).
Variable Infectious Outcome
Septicemia (n = 283) LRTI (n = 11,756) Cutaneous
Cellulitis (n = 2,149)
Herpes Zoster
(n = 837)
Local Candidiasis
(n = 2,592)
HR (95%
CI)
p-
Value
HR (95%
CI)
p-
Value
HR (95%
CI)
p-
Value
HR (95%
CI)
p-
Value
HR (95%
CI)
p-
Value
Age, per 10-y increase 1.12 (1.03,
1.22)
0.006 1.06 (1.05,
1.07)
<0.001 1.38 (1.34,
1.43)
<0.001 1.10 (1.04,
1.15)
<0.001 0.92 (0.89,
0.94)
<0.001
Gender, women versus men 0.89 (0.71,
1.12)
0.31 1.04 (1.00,
1.07)
0.07 1.35 (1.23,
1.48)
<0.001 0.97 (0.84,
1.12)
0.69 1.51 (1.39,
1.64)
<0.001
Underlying disease
Asthma 1 — 1 — 1 — 1 — 1 —
COPD 2.90 (1.38,
6.08)
0.005 1.17 (1.10,
1.23)
<0.001 1.06 (0.88,
1.29)
0.52 1.14 (0.73,
1.49)
0.83 1.00 (0.85,
1.17)
0.98
RA 2.53 (1.09,
5.90)
0.03 0.32 (0.29,
0.36)
<0.001 0.81 (0.65,
1.02)
0.07 1.04 (0.71,
1.51)
0.84 0.46 (0.36,
0.58)
<0.001
IBD 2.85 (1.08,
7.53)
0.03 0.17 (0.15,
0.21)
<0.001 0.76 (0.54,
1.09)
0.14 0.82 (0.47,
1.43)
0.49 0.55 (0.43,
0.71)
<0.001
PMR/GCA 1.20 (0.58,
2.49)
0.62 0.19 (0.17,
0.20)
<0.001 0.50 (0.42,
0.59)
<0.001 0.99 (0.74,
1.32)
0.93 0.34 (0.29,
0.40)
<0.001
Cancer 11.15 (5.78,
21.53)
<0.001 0.63 (0.59,
0.67)
<0.001 1.06 (0.88,
1.28)
0.55 1.76 (1.28,
2.40)
<0.001 2.07 (1.82,
2.35)
<0.001
CTD 4.51 (1.89,
10.75)
0.001 0.28 (0.24,
0.33)
<0.001 1.02 (0.77,
1.35)
0.89 1.66 (1.11,
2.49)
0.01 0.68 (0.53,
0.88)
0.003
Other 3.11 (1.62,
5.99)
0.001 0.35 (0.34,
0.37)
<0.001 0.82 (0.70,
0.95)
0.01 1.10 (0.84,
1.45)
0.48 0.59 (0.52,
0.67)
<0.001
Diabetes, yes versus no 1.91 (1.44,
2.53)
<0.001 1.14 (1.08,
1.20)
<0.001 1.65 (1.48,
1.85)
<0.001 1.25 (1.03,
1.51)
0.03 1.55 (1.39,
1.72)
<0.001
Mean dosage*, per 10-mg/d
increase
1.04 (1.02,
1.05)
<0.001 1.02 (1.01,
1.03)
<0.001 1.03 (1.02,
1.04)
<0.001 1.03 (1.02,
1.05)
<0.001 1.04 (1.03,
1.04)
<0.001
Other immunosuppressant,
yes versus no
0.75 (0.45,
1.23)
0.26 0.72 (0.65,
0.78)
<0.001 0.95 (0.80,
1.13)
0.57 1.40 (1.11,
1.76)
0.004 0.82 (0.69,
0.97)
0.02
*Prednisone equivalent.
CTD, connective tissue disease; IBD, inﬂammatory bowel disease; PMR/GCA, polymyalgia rheumatica/giant cell arteritis; RA, rheumatoid arthritis.
doi:10.1371/journal.pmed.1002024.t003
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Durand and Thomas, the adjusted rate ratios for LRTI, upper urinary tract infection, and sepsis
were 1.48 (95% CI 1.34–1.65), 1.27 (95% CI 1.10–1.46), and 1.63 (95% CI 0.78–3.40), respec-
tively, in 1,664 patients exposed to systemic glucocorticoids for giant cell arteritis compared to
8,078 matched control patients [17]. In a study of patients with systemic lupus erythematosus,
the risk of post-surgical pneumonia (odds ratio [OR] 3.59 [95% CI 2.44–5.30]) and septicemia
(OR 4.23 [95% CI 2.92–6.13]) was significantly increased in those previously exposed to sys-
temic glucocorticoids [7]. It is unclear whether systemic glucocorticoids increase the risk of
non-serious infections in rheumatoid arthritis patients. In a large case control study of more
than 16,000 patients with rheumatoid arthritis published in 2011, the risk of non-serious infec-
tions was higher in those on systemic glucocorticoids (adjusted relative risk [RR] 1.10 [95% CI
1.04–1.16] for those exposed to 5–10 mg/d and 1.85 [95% CI 1.68–2.05] for those exposed to
Table 4. Risk factors for infection in the population exposed to systemic glucocorticoids with data on albumin level and lymphocyte count
(n = 34,401).
Variable Infectious Outcome
Septicemia (n = 112) LRTI (n = 2,530) Cutaneous
Cellulitis (n = 668)
Herpes Zoster
(n = 253)
Local Candidiasis
(n = 779)
HR (95%
CI)
p-
Value
HR (95%
CI)
p-
Value
HR (95%
CI)
p-
Value
HR (95%
CI)
p-
Value
HR (95%
CI)
p-
Value
Age, per 10-y increase 1.14 (0.98,
1.33)
0.08 1.05 (1.02,
1.08)
0.002 1.29 (1.21,
1.38)
<0.001 1.00 (0.91,
1.10)
0.97 0.87 (0.82,
0.91)
<0.001
Gender, women versus men 0.77 (0.53,
1.13)
0.19 1.01 (0.93,
1.10)
0.80 1.28 (1.09,
1.51)
0.003 1.04 (0.80,
1.35)
0.77 1.50 (1.29,
1.74)
<0.001
Underlying disease
Asthma 1 — 1 — 1 — 1 — 1 —
COPD 2.00 (0.61,
6.52)
0.25 1.20 (1.03,
1.40)
0.02 1.00 (0.68,
1.47)
0.99 2.10 (1.00,
4.39)
0.05 1.00 (0.71,
1.39)
0.98
RA 0.47 (0.08,
2.61)
0.39 0.43 (0.36,
0.52)
<0.001 0.87 (0.60,
1.26)
0.46 1.47 (0.73,
2.98)
0.28 0.41 (0.28,
0.61)
<0.001
IBD 2.21 (0.49,
9.98)
0.30 0.20 (0.13,
0.29)
<0.001 0.63 (0.32,
1.25)
0.19 0.64 (0.18,
2.30)
0.49 0.64 (0.41,
1.01)
0.05
PMR/GCA 0.85 (0.28,
2.63)
0.78 0.25 (0.22,
0.29)
<0.001 0.52 (0.37,
0.72)
<0.001 1.50 (0.78,
2.87)
0.22 0.41 (0.31,
0.56)
<0.001
Cancer 5.17 (1.82,
14.65)
0.002 0.86 (0.74,
0.99)
0.04 1.01 (0.71,
1.45)
0.96 2.08 (1.02,
4.24)
0.04 2.04 (1.56,
2.65)
<0.001
CTD 2.76 (0.73,
10.50)
0.14 0.36 (0.27,
0.47)
<0.001 0.87 (0.54,
1.42)
0.58 1.94 (0.88,
4.24)
0.10 0.65 (0.42,
1.00)
0.05
Other 1.93 (0.68,
5.45)
0.22 0.49 (0.43,
0.56)
<0.001 1.01 (0.74,
1.37)
0.97 1.62 (0.86,
3.06)
0.14 0.69 (0.53,
0.89)
<0.001
Diabetes, yes versus no 1.49 (0.96,
2.32)
0.08 1.01 (0.91,
1.12)
0.88 1.43 (1.19,
1.72)
<0.001 1.03 (0.73,
1.44)
0.87 1.30 (1.08,
1.56)
0.006
Mean dosage*, per 10-mg/d
increase
1.09 (1.04,
1.14)
<0.001 1.06 (1.04,
1.08)
<0.001 1.07 (1.04,
1.12)
<0.001 1.06 (1.00,
1.13)
0.04 1.09 (1.07,
1.10)
<0.001
Other immunosuppressant, yes
versus no
0.52 (0.23,
1.18)
0.12 0.83 (0.72,
0.95)
0.006 0.95 (0.75,
1.20)
0.64 1.64 (1.17,
2.29)
0.004 0.77 (0.60,
0.99)
0.04
Albumin level, per 1-g/l increase 0.93 (0.90,
0.96)
<0.001 0.98 (0.97,
0.98)
<0.001 0.96 (0.94,
0.97)
<0.001 1.00 (0.97,
1.02)
0.85 0.96 (0.95,
0.97)
<0.001
Lymphocyte count, per 1,000/
mm3 increase
0.96 (0.90,
1.02)
0.19 1.00 (0.99,
1.01)
0.96 0.98 (0.95,
1.00)
0.03 0.99 (0.97,
1.02)
0.69 0.99 (0.98,
1.01)
0.37
*Prednisone equivalent.
CTD, connective tissue disease; IBD, inﬂammatory bowel disease; PMR/GCA, polymyalgia rheumatica/giant cell arteritis; RA, rheumatoid arthritis.
doi:10.1371/journal.pmed.1002024.t004
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20 mg/d) than in the unexposed group [18]. On the other hand, a meta-analysis of RCTs
published the same year showed no increase in the risk of non-serious infections (RR 1.05
[95% CI 0.89–1.24] when the RCTs considered to report predominantly these events were ana-
lyzed) [19]. In contrast, the risk of common serious infections (e.g., bacterial pneumonia, her-
pes zoster, and skin or soft tissue infections) increased in these patients [19,20]. In patients
with inflammatory bowel disease, the risk of serious common bacterial infections was increased
by four times in those exposed to systemic glucocorticoids (adjusted RR 4.0 [95% CI 2.5–6.6])
[4]. Regarding viral infections, glucocorticoids increase the risk of viral reactivation (e.g., hepa-
titis B virus and herpes zoster) [21,22]. Whether or not viral infections are more common or
severe in those exposed to glucocorticoids is still unclear [23–27]. There are numerous case
reports of severe scabies (i.e., Norwegian) or dermatophytosis (i.e., deep dermatophyte infec-
tion) after exposure to glucocorticoids [28–32]. However, an increase in risk of common pre-
sentations of these infections in people exposed to glucocorticoids has never been
demonstrated.
Regarding our results, we found that the risk of local candidiasis was much higher than that
of bacterial, viral, or parasitic infections, with the exception of LRTI. There are many glucocor-
ticoid-induced biological effects that result in increased susceptibility to fungal infections [8].
These include direct or indirect effects on lymphocytes, neutrophils, or eosinophils, but also
direct effects on candida growth, morphogenesis, and virulence [8,33,34]. We also found that
the risk of LRTI was much higher than the risk of other bacterial infections such as septicemia
or cutaneous cellulitis. A significantly increased risk of pneumonia or recurrent pneumonia
has previously been demonstrated with inhaled glucocorticoids in patients with asthma or
COPD [35–37]. We further found that the risk of infection was associated with the underlying
disease. Overall, patients with polymyalgia rheumatica/giant cell arteritis were at lower risk.
This finding cannot be easily explained but is in accordance with previous studies demonstrat-
ing a low risk of bacterial or viral infection in these patients [17,38]. Lastly, we found that for
LRTI and local candidiasis, the relative increase in risk was highest during the first weeks of
exposure and markedly decreased thereafter. Whether the relative risk of infection induced by
systemic glucocorticoids is more related to the treatment daily dosage or to the treatment dura-
tion is still unknown and debated. A meta-analysis showed that the risk was highest during the
first days/weeks of therapy than for longer exposure [3]. In the large study by Dixon et al. [39],
the risk of serious infection was higher in patients exposed for 1 mo to 30 mg/d of prednisolone
equivalent (adjusted OR 1.84 [95% CI 1.58–4.00]) than in those exposed for 6 mo to 5 mg/d
(adjusted OR 1.46 [95% CI 1.31–1.65]).
Biologically, a low albumin level was strongly associated with the risk of infection. The low
albumin level could be indirectly (i.e., by being a marker of the malnutrition–inflammation syn-
drome) or directly (i.e., as an etiological factor) responsible for this higher risk of infection. For
instance, a low albumin level is associated with a higher free glucocorticoid fraction, i.e., the bio-
logically relevant fraction of the drug interacting with the glucocorticoid receptor [40]. A corre-
lation between increased free fraction of the drug due to low albumin concentration and
glucocorticoid adverse effects has previously been evidenced during prednisone therapy [41].
Our study has several strengths. We used a large population-based sample of patients of
both sexes, across all adult age groups, and with many underlying diseases and comorbidities.
This enabled us to compare the impact of systemic glucocorticoids on different bacterial, viral,
fungal, and parasitic infections using the same method of assessment. Moreover, the study pop-
ulation is an unselected population of patients exposed to systemic glucocorticoids in primary
care; to our knowledge, such a study has never been done previously.
However, there are also some limitations to our study. First, the use of anonymized elec-
tronic medical records and reliance on diagnostic codes could have resulted in some degree of
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misclassification of the infectious outcomes. However, we chose to study infections currently
seen in primary care. Second, a reporting bias is possible, as general practitioners could be
more prone to record an infection in those exposed to glucocorticoids. However, very different
relative risks were observed for the studied infections, and we believe that it is unlikely that gen-
eral practitioners would more systematically record local candidiasis than herpes zoster or sep-
ticemia in those prescribed glucocorticoids. Further, such bias is unlikely to occur for severe
events such as septicemia. Third, we chose to study only events for which a precise diagnostic
code was recorded. For instance, for LRTI, we did not include events recorded as “chest infec-
tions,” and we included only bacterial cutaneous infections that were recorded as “cutaneous
cellulitis” or “erysipelas,” not those reported as “bacterial skin or soft tissue infection.”Hence,
the proportions experiencing the outcomes of interest as reported in Table 2 are likely to be
much lower than what really occurred. For this reason, we chose not to assess the incidence
rates of the infections of interest in the study population, as they would be underestimates of
the true incidence rates. Fourth, we did not observe an increase in the risk of scabies or varicella
in glucocorticoid-exposed patients, but the number of records of these events was small and
statistical power was therefore limited. Fifth, no data were available regarding adherence to glu-
cocorticoid treatment. We found that those exposed to other immunosuppressants in addition
to glucocorticoids may be less likely to develop infections (with the exception of herpes zoster),
but this finding does not exclude the possibility that those whose conditions are well-controlled
with other immunosuppressants may be less adherent to glucocorticoids, which are perceived
by patients as a dangerous drug [42]. Sixth, even though we tried to assess the impact of the
most obvious potential unmeasured confounders (disease severity for those with asthma/
COPD and use of concomitant chemotherapy for those with cancer), it is likely that some
other confounders were not accounted for in the analyses. We cannot tell whether adjusting for
these unmeasured confounders would have radically changed the findings. Seventh, for LRTI
and local candidiasis, the relative decrease in risk over the duration of exposure can be
explained, at least partly, by the fact that the most at-risk patients may have developed the
infectious condition during the first weeks or months of glucocorticoid exposure, which could
have led to an early cessation of glucocorticoids. Therefore, those who are still exposed to glu-
cocorticoids after many months may be patients who are inherently at low risk of LRTI or local
candidiasis. Similarly, it can be assumed that there are some clinical factors that influence gen-
eral practitioners in their decision to prescribe more or less time on glucocorticoids (e.g., sever-
ity of the underlying disease, general health state of the patient). If these factors are associated
with the risk of infection, they could contribute to the patterns of time-dependent risks that
were observed in our study. However, if these were important cofounders, we believe that the
same time-dependent patterns would have been observed for all assessed outcomes. Eight,
while the duration of a prescription can easily be defined for short-term glucocorticoid expo-
sures, some may argue that duration may be less precise for long-term exposures. However,
even for long-term prescriptions, treatment renewal is usually made every 1 to 3 mo, which
allowed us to estimate fairly precisely when treatment ended, with an uncertainty margin of no
more than a few days. Lastly, some treatments, such as chemotherapy or use of biologicals pre-
scribed in hospital, were not taken into account in the analyses as they are not prescribed in
primary care and are therefore not recorded in THIN.
Our estimates have several practical implications. First, patients prescribed systemic gluco-
corticoids are at very high risk of LRTI. This should be considered when prescribing systemic
glucocorticoids, in particular in those with asthma or COPD [43], and when deciding which
patients might need more intensive follow-up and immunization [44]. Further, a skin and
mucous examination is probably advisable in patients exposed to systemic glucocorticoid ther-
apy for more than a few days so as to screen out (and treat) both candidiasis and foot mycosis
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(as a risk factor for cutaneous cellulitis). Lastly, hypoalbuminemia seems to be a biological fac-
tor as important as diabetes in increasing the risk of infections in glucocorticoid-exposed
patients. While fasting glycemia is often monitored in these patients, screening for albumin
level is not currently recommended at baseline and during glucocorticoid exposure [45].
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Editors’ Summary
Background
Throughout life, our immune system protects us from attack by disease-causing organ-
isms. When a virus, bacterium, fungus, or parasite enters the human body, the immune
system detects the invader and triggers a response that kills or neutralizes it. Normally, the
immune system discriminates perfectly between foreign invaders and the body’s own cells
and tissues, but sometimes it goes awry and begins to attack “self,” resulting in the devel-
opment of an autoimmune disease such as rheumatoid arthritis (in which the immune sys-
tem attacks the joints) or lupus erythematosus (in which the immune system attacks
numerous tissues and organs). Immune system dysfunction is also involved in chronic
inflammatory conditions. Tissue inflammation (pain, heat, redness, and swelling) is part
of the normal immune response, but uncontrolled inflammation underlies sepsis (a sys-
temic inflammatory condition that sometimes develops after a localized infection) and
lung conditions such as asthma and chronic obstructive pulmonary disease.
WhyWas This Study Done?
Inflammatory diseases and autoimmune diseases are often treated with glucocorticoids—
drugs with immunosuppressive and anti-inflammatory properties. At any one time, more
than 1% of the US and UK population is receiving systemic glucocorticoid therapy
(whole-body therapy often given as a pill) to treat an autoimmune or inflammatory condi-
tion or to treat cancer or prevent organ rejection after transplantation. But, although pred-
nisolone, dexamethasone, and other glucocorticoids are effective treatments for these
conditions, long-term use of oral glucocorticoids is associated with serious side effects,
including an increased infection risk. Several studies have investigated the overall risk of
infection in specific populations receiving glucocorticoids, but little is known about the
risk of individual common infections among people in the general population taking glu-
cocorticoids. Here, the researchers undertake a population-based cohort study—an obser-
vational investigation that compares specific outcomes in groups (cohorts) of people from
the general population with different baseline characteristics—to discover more about
common infections in patients prescribed systemic glucocorticoids in primary care.
What Did the Researchers Do and Find?
Using The Health Improvement Network (THIN) primary care database, the researchers
identified 275,072 adults prescribed oral glucocorticoids in the UK between 2000 and
2012, a random sample of people not prescribed glucocorticoids but with a diagnosis of
the same underlying disease as the exposed individuals, and cases of infection in both
cohorts. Compared to the unexposed group, the glucocorticoid-exposed group had an
increased risk of three bacterial infections (septicemia, lower respiratory tract infection
[LRTI], and cutaneous cellulitis), one viral infection (herpes zoster), and one fungal infec-
tion (local candidiasis) but no increased risk of varicella virus infection, dermatophytosis
(a fungal infection), or scabies (a parasitic infection). The increased risk was highest for
LRTI—the risk of LRTI was nearly six-fold higher in the glucocorticoid-exposed group
than in the unexposed group. The relative increase in infection risk was similar whatever
the duration of glucocorticoid therapy except for LRTI and local candidiasis, for which it
was higher in the first few weeks of treatment. The risk of infection increased with age and
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was higher in people with diabetes, in people given high glucocorticoid doses, and in peo-
ple with low blood albumin levels. Finally, the risks of different infections depended on the
disease for which glucocorticoids were prescribed.
What Do These Findings Mean?
These findings show that the risk of several (but not all) common bacterial, viral, and fungal
infections was higher among people prescribed glucocorticoids for a range of underlying
diseases than among people matched for age, gender, and underlying disease who were not
prescribed glucocorticoids. Notably, the relative risk of LRTI and local candidiasis was par-
ticularly high during the first weeks of glucocorticoid exposure. Several aspects of the study
design may affect the accuracy of these findings. For example, the use of medical records
may have resulted in some misclassification of infectious outcomes. However, the finding
of a high risk of LRTI in patients prescribed systemic glucocorticoids should be considered
before prescribing these drugs, particularly in patients with asthma or chronic obstructive
pulmonary disease. The finding of an association between low blood albumin level and
increased infection risk needs further investigation to determine whether a low albumin
level is a direct risk factor for infection or a marker for other underlying causes of debilita-
tion that increase the risk of infection, but it may be worth considering monitoring albumin
level before and during glucocorticoid treatment.
Additional Information
This list of resources contains links that can be accessed when viewing the PDF on a device
or via the online version of the article at http://dx.doi.org/10.1371/journal.pmed.1002024.
• This study is further discussed in a PLOS Medicine Perspective by Lionel Rostaing and
Paolo Malvezzi
• The UK National Health Service Choices website provides information about
corticosteroids (glucocorticoids are a specific type of corticosteroids)
• The Mayo Clinic has an article about the benefits and risks of corticosteroids
• Wikipedia has information on autoimmune disease, inflammatory disorders, and
glucocorticoids (note that Wikipedia is a free online encyclopedia that anyone can edit;
available in several languages)
• MedlinePlus provides links to further information about autoimmune diseases and
about corticosteroids
• More information about The Health Improvement Network database of anonymized
electronic medical records is available
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